🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 25% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

8.5 Gram(s) Serving Size
5 Servings
Other Combinations Product Type
25% Evidence Coverage

Supplement Facts — Evidence Check

25 mg NE (156% DV)
✅ 1.8× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 25mg UL 35mg
500 mcg (20834% DV)
📊 208.3× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.5mg
Sodium
100 mg (4% DV)
Superhuman Pump & Performance Matrix
Superhuman Energy Matrix
Superhuman Fat Burn Matrix
Superhuman Focus Matrix
Superhuman Absorption Matrix
12.5 mg NE (78% DV)
✅ Within RDA (0.9× RDA of 14 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 12.5mg UL 35mg
250 mcg (10417% DV)
📊 104.2× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.25mg
Sodium
50 mg (2% DV)
Superhuman Pump & Performance Matrix
Superhuman Energy Matrix
Superhuman Fat Burn Matrix
Superhuman Focus Matrix
Superhuman Absorption Matrix

Other Ingredients

Malic Acid Natural & Artificial Flavor Silicon Dioxide Calcium Silicate Sucralose Acesulfame Potassium FD&C Yellow 5 FD&C Blue 1

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

🧪 Formulation Notes

2-in-1 fat burning pre-workout

Smurf juice blue gummy bear Natural and artificial flavors

Additional Information

10 delicious servings

Product Details

DSLD Entry Date 2023-01-23
Product Type Other Combinations
Form Powder
Brand Alpha Lion
DSLD ID 273235
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →